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We present our initial experience with CyberKnife stereotactic body radiation therapy
(SBRT) in a heavily pretreated group of patients with liver metastases and primary liver
tumors. From October 2007 to June 2009, 48 patients were treated at the Philadelphia
CyberKnife Center for liver metastases or primary liver tumors. We report on 30 patients
with 41 discrete lesions (1–4 tumors per patient) who received an ablative radiation dose
(BED≥79.2Gy10=66Gy EQD2). The treatment goal was to achieve a high SBRT dose
to the liver tumor while sparing at least 700cc of liver from radiation doses above 15Gy.
Twenty-threepatientsweretreatedwithSBRTformetastaticcancertotheliver;theremain-
der (n=7) were primary liver tumors. Eighty-seven percent of patients had prior systemic
chemotherapy with a median 24months from diagnosis to SBRT; 37% had prior liver
directed therapy. Local control was assessed for 28 patients (39 tumors) with 4months or
more follow-up. At a median follow-up of 22months (range, 10–40months), 14/39 (36%)
tumors had documented local failure. A decrease in local failure was found with higher
doses of SBRT (p=0.0237); 55% of tumors receiving a BED≤100Gy10 (10/18) had local
failure compared with 19% receiving a BED>100Gy10 (4/21).The 2-year actuarial rate of
local control for tumors treated with BED>100Gy10 was 75% compared to 38% for those
patientstreatedwithBED≤100Gy10(p=0.04).Atlastfollow-up,22/30patients(73%)had
distant progression of disease. Overall, seven patients remain alive with a median survival
of 20months from treatment and 57months from diagnosis. To date, no patient expe-
rienced persistent or severe adverse effects. Despite the heavy pretreatment of these
patients, SBRT was well tolerated with excellent local control rates when adequate doses
(BED>100Gy10) were used. Median survival was limited secondary to development of
further metastatic disease in the majority of patients.
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INTRODUCTION
The treatment of liver metastases and primary liver tumors has
evolved with surgery as the current standard of care for local-
ized lesions in medically operable patients (Robertson et al.,
2009). Some patients with extensive liver metastasis at presen-
tation can become surgical candidates following chemotherapy,
as improved drugs with better response rates have been devel-
oped (Adam et al., 2009). However, only a limited proportion of
liver metastases patients (10–20%) can ultimately undergo sur-
gical resection because of associated comorbidities, age, disease
extent, and patient wishes.
Alternativeliverdirectedtreatmentapproachesforunresectable
liver metastases and primary liver tumors include radiofrequency
ablation, cryotherapy, and chemoembolization. These techniques
have selection criteria which limit eligibility such as size,location,
and number of tumors (Kemeny, 2006). Stereotactic body radia-
tion therapy (SBRT) is used to deliver ablative doses of radiation
toanextracranialtargetwithhighprecisionandrapidfall-off that
spares surrounding tissues. Early SBRT results revealed excellent
tolerance and local control rates for liver metastases and primary
livertumors(Hoyeretal.,2006;MendezRomeroetal.,2006;Wulf
etal.,2006;Leeetal.,2009;Rusthovenetal.,2009).TheCyberKnife
system (Accuray Inc., Sunnyvale, CA, USA) has several features
that make it well suited for liver SBRT. Radiation delivery is per-
formed by a linear accelerator mounted on a robotic arm that
accuratelyalignsanddeliverstheradiationintheformofhundreds
of “beamlets”which allows optimization of the tumor dose while
sparing surrounding normal tissue. In addition, the CyberKnife’s
Synchrony motion tracking system, which uses real-time imaging
and ﬁducial tracking, improves targeting accuracy because of the
ability to track the tumor, and adjust the beam during respira-
tion (Kilby et al.,2010).With better accuracy,tighter margins and
higher doses are possible. Initial reports on CyberKnife SBRT for
liver tumors have shown promising local control with minimal
toxicity for select patients with hepatocellular carcinoma (HCC;
Choi et al.,2008; Louis et al.,2010),metastases (Ambrosino et al.,
2009; Stintzing et al., 2010), and mixed populations of both HCC
and metastases (Goodman et al.,2010).
In this report we describe our initial experience with
CyberKnife SBRT in a heavily pretreated group of patients with
liver metastases and primary liver tumors with regard to SBRT
technique and outcome.
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MATERIALS AND METHODS
PATIENTS
From October 2007 to June 2009, 48 patients were treated at the
Philadelphia CyberKnife Center for liver metastases or primary
livertumors.Patientsweredividedintoablative(BED≥79.2Gy10
equivalent to 2Gy×33, 12Gy×3, or 8.5Gy×5) and non-
ablative (BED<79.2Gy10) populations. The BED was calculated
asBED=D∗(1+d/α/β)whereD isthetotaldose,d isthedoseper
fraction and the α/β ratio for the tumor was 10Gy. The total bio-
logicallyequivalentdosein2Gyfractions,EQD2,wascalculatedas
EQD2=D∗[(d +α/β)/(2Gy+α/β)]. An ablative dose regimen
was deﬁned as at least 66Gy in 2Gy per fraction (EQD2=66Gy)
based on conventional fractionation. For this IRB approved retro-
spective study,only those patients treated with an ablative dose of
radiation (BED≥79.2Gy10) were further studied and reported.
No patient had impaired liver function or more than four discrete
lesions.
TREATMENT
Stereotactic body radiation therapy was delivered using the
CyberKnife system (Accuray Incorporated, Sunnyvale, CA, USA)
with 6mV photons. Multiplan software was used for treatment
planning. All patients had one to three gold ﬁducial markers
placed under CT guidance within each tumor for tracking during
treatment. Triple phase contrast enhanced CT was obtained for
treatment planning 7–10days following ﬁducial placement. Liver
windows with contrast were usually used for contouring the clini-
caltargetvolume(CTV),however,onoccasionthelivermetastases
were more visible on liver windows without contrast so both were
obtainedineachpatient.Inadditiontothelivertumor/metastases
(CTV), normal tissues in proximity to the tumor were contoured
including the bowel, heart, rib, and kidney. Normal tissue dose
constraints were applied as deﬁned by Timmerman (2008).T h e
entire liver was contoured in all patients and the tumor volume
subtracted for dose volume histogram analysis. The gross target
volume (GTV) equaled the CTV. The planning target volume was
deﬁned by a uniform 5mm CTV expansion. If necessary, due to
normal tissue proximity, margins were reduced to 3mm or less.
Dose was generally prescribed to the 60–80% isodose line to cover
95%ofthePTVwiththeprescribeddose.Bothisocentricandnon-
isocentrictreatmentplanswereuseddependingonpatientspeciﬁc
variables (liver size and tumor shape). However, non-isocentric
treatment plans were used in the majority of patients. Treatment
was delivered using between 80 and 150 beams. Synchrony track-
ingwasutilizedinallpatientstoaccountforrespiratorymovement
of the tumor by tracking the ﬁducials throughout the respiratory
cycle. During treatment, tracking images were taken every three
beams.
FOLLOW-UP AND STATISTICAL ANALYSIS
Patients were generally seen at 1 and 3months after treatment
and every 6months thereafter. Acute toxicities were deﬁned as
those occurring within 3months of treatment. All toxicities were
graded using the Radiation Therapy Oncology Group (RTOG)
scoring system (Cox et al., 1995). PET/CT, CT, or MRI imaging
was obtained at 3–6months follow-up to assess local control. For
HCC CT or MRI was preferred. The RECIST 1.1 (Therasse et al.,
2000) and PERCIST 1.0 (Wahl et al., 2009)c r i t e r i aw e r eu s e dt o
deﬁne local failure depending on the availability of PET/CT. In
either case, each lesion was evaluated independently if more than
one lesion was treated per patient. In the absence of PET/CT,local
failure was deﬁned as ≥5mm net increase in the target lesion’s
longestdiameter(Therasseetal.,2000);otherwise(preferred)local
failure was deﬁned as a persistently metabolically active mass or
recurrenceof metabolicactivitywithamaximumSUVaboveliver
background activity. Pretreatment PET/CT with a metabolically
active target lesion was required for PET/CT evaluation (Wahl
et al., 2009). Unpaired t-tests and chi-squared analysis were used
to assess statistical signiﬁcance. Kaplan–Meier local control and
survival analysis was performed.
RESULTS
PATIENTS
The 30 patients treated with an ablative SBRT dose
(BED≥79.2Gy10) had 41 discrete lesions (range 1–4 tumors per
patient). The majority of patients were treated for liver metas-
tases (n =23) with the rest either cholangiocarcinoma (n =4) or
HCC (n =3). Median age of all patients was 64years (range 47–
89). The patients were heavily pretreated. Eighty-seven percent
of patients (n =26) had prior systemic chemotherapy for treat-
ment of liver metastases or liver tumor. Thirty-seven percent of
patients (n =11) had prior liver directed therapy which included
surgical resection, chemoembolization, radiofrequency ablation,
photodynamic therapy, or previous external beam radiation with
four patients having more than one prior liver directed treat-
ment. The median time from diagnosis to SBRT for all patients
was 26months (range, 1–95months). Patient characteristics are
summarized in Table 1.
TREATMENT FACTORS
The treatment planning goal was to spare at least 700cc of
uninvolved liver from doses of radiation greater than 15Gy
to maintain hepatic function (Schefter et al., 2005). Thus, the
pretreatment liver and tumor volumes were important factors
determining prescribed dose as detailed in Table 1. Median pre-
treatment liver volume was 1464cc (range 907–2450cc). Median
volume of liver receiving ≤15Gy was 1142.5cc (range 662.2–
2000.1cc) Patients with previous liver directed therapy had a
lower median pretreatment liver volume and median volume
of liver receiving ≤15Gy compared to those patients with no
previous liver directed therapy. Radiation doses ranged from
12Gy×3 fx (BED=79.2Gy10, EQD2=6 6 G y )t o2 0 G y ×3f x
(BED=180Gy10, EQD2=150Gy) with the most common frac-
tionation being 12.5Gy×3 fx (BED=84.4 Gy10,EQD2=70Gy)
prescribed to the 60–80% isodose line to cover 95% of the PTV.
Over half of the patients had PET/CT for local control assess-
mentwith79%of localfailuresdocumentedbyPET/CT(Table 2).
Figure 1 shows the SBRT dose distribution and correspond-
ing response as assessed by PET/CT of a patient who received
sequential courses of CyberKnife SBRT to two hepatic metastases.
CLINICAL OUTCOMES
At 22months (range,10–40months) median follow-up,14 (36%)
of the 39 tumors in the 28 patients with more than 4months
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T a b l e1|P atient characteristics and treatment parameters.
Patients 30
Lesions 41
Age
Median 64
Range 47–89
Liver lesions per patient Number Percent
12 2 7 3
26 2 0
3 1 3.33
4 1 3.33
Primary liver malignancy (n =7)
Cholangiocarcinoma 4 13.33
Hepatocellular carcinoma 3 10.00
Metastatic disease (n =23)
Colorectal cancer 15 50.00
Breast cancer 3 10.00
Esophageal cancer 1 3.33
Gastrointestinal stromal tumor 1 3.33
Pancreatic cancer 1 3.33
Non-small cell lung cancer 2 6.67
Previous systemic therapy
Yes 26 86.67
No 1 3.33
Unknown 3 10.00
Previous liver directed therapy
Yes 11 36.67
No 19 63.33
Surgical resection 2 6.67
Chemoembolization (CE) 2 6.67
Surgical resection, RFA 2 6.67
Radiofrequency ablation (RFA) 1 3.33
Radiation therapy 1 3.33
CE, RFA 1 3.33
Surgical resection, CE, RFA 1 3.33
Photodynamic therapy (PDT) 1 3.33
Pretreatment liver volume (cc) Median Range
All patients 1464 907 .8–2450
Previous liver directed therapy 1346.4 1118–2253
No previous liver directed therapy 1638.4 907 .8–2450
Pretreatment tumor volume (cc)
All tumors 25.33 0.534–316
Largest per patient 46.85 1.77–316
Pretreatment median total per patient
tumor volume (cc)
All patients 60.9 2.29–316
Previous liver directed therapy 60.7 10.3–201.7
No previous liver directed therapy 61.2 2.29–316
Volume of liver receiving ≤15Gy (cc)
All patients 1142.5 662.2–2000.1
Previous liver directed therapy 1041.4 662.2–1901.9
No previous liver directed therapy 1215.3 689.0–2000.1
Prescribed Dose (BED) Number Percent
12 Gy ×3 (79.2Gy10, EQD2=66Gy) 2 6.67
12.5Gy×3(84.38Gy10, EQD2=70Gy) 17 56.67
(Continued)
10 Gy ×5 (100Gy10, EQD2=84Gy) 1 3.33
14 Gy ×3 (100.8Gy10, EQD2=84Gy) 3 10.00
15 Gy ×3 (112.5Gy10, EQD2=94Gy) 10 30.00
17 .5Gy×3(144.4Gy10, EQD2=120Gy) 4 13.33
20Gy×3 (180Gy10, EQD2=150Gy) 4 13.33
Treatment planning
Isocentric 13 31.70
Non-isocentric 28 68.30
Table 2 | Summary of the follow-up imaging performed denoting the
imaging modality used in the assessment of the 14 local failures.
Number of tumors Percent
FOLLOW-UP IMAGING
PET/CT 22 54
CT 13 32
MRI 3 7
PET/CT, MRI 2 5
Surgery 1 2
LOCAL FAILURE EVALUATION
PET/CT 11 79
CT 3 21
follow-up had local failure. Median time to local failure from
SBRT was 13months (range, 6–21months). One- and two-year
actuarial local control rates are 92 and 56%, from time of SBRT
(Figure 2A). The 2-year actuarial rate of local control for tumors
w i t haC T Vo f≤25.3cc was 57% compared to 52% for those
patients with a CTV of >25.3cc (Figure 2B). A decrease in local
failure was found with higher SBRT dose (p=0.0237);55% of the
tumorsreceivingaBED≤100Gy10(10/18)hadlocalfailurecom-
paredwith19%treatedwithaBED>100Gy10(4/21).The2-year
actuarial rate of local control for tumors treated with BED>100
Gy10 was 75% compared to 38% for those patients treated with
BED≤100Gy10 (Figure 2C, p=0.04). Distant disease progres-
sion included all failures outside the treatment volume including
distant liver sites. Twenty-two of 30 patients (73%) had distant
disease progression at last follow-up,with distant failure the most
common pattern of failure.
Seven (23%) patients remain alive with a median 20months
survival from SBRT and 57months from diagnosis. One-, two-,
and three-year actuarial survival rates are 73, 31, and 17%
from SBRT (Figure 3A). Given the heavily pretreated popula-
tion, actuarial survival from diagnosis is also presented. Three-,
ﬁve-, and seven-year actuarial survival rates are 73, 44, and 25%
from diagnosis (Figure 3B). The 1-year actuarial rate of over-
all survival for those patients with a largest CTV ≤46.85cc was
86% compared to 60% for those with a largest CTV >46.85cc
(Figure 3C). At 2years this difference was less (35 vs 26%,
p =0.0899). The 2-year actuarial rate of overall survival for those
patients treated with a BED≤100 Gy10 was 21% compared
to 42% for those treated with a BED>100 Gy10, not statisti-
cally signiﬁcant (Figure 3D). At 3years this difference was less
(14 vs. 16%).
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FIGURE 1 | Example of complete response to SBRT assessed by
PET/CT. A 63-year-old African American male with two metachronous liver
metastases 4years after colon resection (T3N0 adenocarcinoma). He
received 2years of chemotherapy for the liver metastases with progression
and was referred for SBRT. (A)Tumor 1 and (B) tumor 2. Shown in each
panel are the (a) axial and (b) coronal views of the pretreatment PET/CT; the
(c) axial and (d) coronal views of the post-treatment PET/CT and the (e) axial
and coronal treatment planning CT denoting the SBRT dose distribution.
Treatment was well tolerated by all patients with no observed
acute toxicities and minimal late toxicities observed. One patient
with a solitary liver metastasis (CTV 141cc) developed a grade
3 small bowel obstruction 5months after SBRT. Following resec-
tion, pathology revealed poorly differentiated metastatic adeno-
carcinoma involving the small bowel mesentery and abdominal
wall along with separate specimens from the abdominal wall and
umbilical hernia. One patient with a large gastrointestinal stro-
mal tumor (CTV 123cc) developed a grade 2 liver abscess in the
treatment volume 16months after receiving SBRT of 37.5Gy in 3
fractions. Hospitalization, drainage catheter and antibiotics were
required. This patient’s most recent CT demonstrated progres-
sion of disease outside the treated mass with continued abscess
within the treated mass and was coded as a local failure by size
criteria. Both patients had local/regional failure that could have
accounted for the presumed complications. One patient with a
solitary liver metastasis adjacent to ribs (CTV 10cc) experienced
painwithagrade4ribfracture19monthsaftertreatmentwithno
evidenceoflocalfailure.Retrospectivedosecalculationtoadjacent
ribs revealed 9.5cc of total rib volume received over 30Gy.
One patient received treatment for a new liver metastasis
9months after initial SBRT and one patient was retreated for local
failure 22months after initial SBRT; both patients’second courses
FIGURE 2 | Local control analysis (A) from time of SBRT.
(B) Comparison of local control for tumors with a CTV ≤25.3cc to those
with a CTV >25.3cc. (C) Comparison of local control for those tumors
receiving a BED10 of ≤100Gy10 to those receiving a BED10>100Gy10.
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FIGURE 3 | Survival analysis (A) from time of SBRT and (B)
from time of diagnosis. (C) Comparison of overall survival for
patients with a largest CTV ≤46.85cc to those with a largest CTV
>46.85cc. (D) Comparison of overall survival for those patients
receiving a BED10 of ≤100Gy10 to those receiving a
BED10>100Gy10.
of treatment are included in this analysis. The patient retreated
for local failure received two courses of SBRT, each 45Gy×3 fx.
At last follow-up by PET/CT, this patient has local control in the
treated lesion, but new distant liver metastases. Five months after
retreatment,he had grade 2 toxicity consisting of abdominal pain,
inﬂammation of the second portion of the duodenum and pelvic
ﬂuidbyCTscan,buttheseSBRTrelatedsymptomsresolvedwithin
7months of retreatment.
DISCUSSION
While SBRT for liver metastases and primary tumors is a rel-
atively new concept, a large body of retrospective literature is
available describing early treatment results (Hoyer et al., 2006;
Mendez Romero et al., 2006; Wulf et al., 2006; Lee et al., 2009;
Rusthoven et al., 2009; van der Pool et al., 2010; Chang et al.,
2011; Vautravers-Dewas et al., 2011) including four prospective
Phase I studies (Schefter et al., 2005; Lee et al., 2009; Goodman
et al.,2010; Rule et al.,2011). The earliest phase I trial reported by
Schefteretal.(2005)establishedthebeneﬁtandsafetyof SBRTfor
liver metastases with eligible patients having 1–3 lesions, tumor
diameters <6cm, and adequate liver function. Dose limiting tox-
icity was not found despite escalation to 60Gy in 3 fractions.
Dose volume constraints ensured at least 700cc of uninvolved
liver received <15Gy. When we began SBRT this was the only
published prospective study, however, early retrospective series
(Hoyer et al., 2006; Mendez Romero et al., 2006; Wulf et al.,
2006; Lee et al., 2009) were available which helped to initiate
our program in 2007. Based on these studies, our initial dose
fractionation schema was 12.5Gy×3 fractions. As our experi-
ence and the literature matured, we progressively increased dose.
Because of the dose prescription variability in this series, a dose
response analysis was possible which documented increased local
control for a BED>100 Gy10. McCammon et al. (2009) reviewed
their lung and liver experience with stereotactic radiation and
found a dose response with increased nominal dose of 54Gy or
greater in 3 fractions. Their 3-year actuarial local control rate was
89.3% for a dose >54Gy compared to 59 and 8.1% for those
treated to 36–53.9Gy and <36Gy, respectively. Rule et al. (2011)
revealed improved local control of 100% at 2years in a phase I
trial with dose escalation to 60Gy in 5 fractions for liver metas-
tases compared to 56% local control with 30Gy in 3 fractions. A
pooled analysis of patients treated with SBRT for colorectal liver
metastases from Stanford University, Princess Margaret Hospital
and University of Colorado revealed total dose, dose per fraction
and BED to be signiﬁcant for local control by lesion in multi-
variate analysis. They estimated a dose of 46–54Gy in 3 fractions
or a BED of 117 Gy10 (EQD2=98Gy) would be required for
1-year local control rates >90% (Chang et al., 2011). Vautravers-
Dewas et al. (2011) did not demonstrate a dose response in 42
patients with 62 metastases, however, their dose prescription was
limited to 40Gy in 4 fractions and 45Gy in 3 fractions (BED
80–113Gy10, EQD2=66–94Gy). The current series is consis-
tent with the above literature which conﬁrms adequate dose is
requiredforlocalcontrolwithaBED>100Gy10(EQD2=90Gy)
suggested. However, given the mixed population of primary and
metastatic tumors combined with a range of primary tissue types,
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further study is necessary to determine the optimal BED based on
histology.
Observed toxicities in the current study were generally mild
withonlyonepatientexperiencinggrade3orgreatertoxicitywith-
out recurrent disease which could account for the toxicity. This
patient with a solitary liver metastases adjacent to ribs developed
rib pain and fracture 19months following SBRT. Extrapolating
from the SBRT lung literature reveals that rib fractures are the
most common late toxicity from SBRT (Pettersson et al., 2009;
Nambu et al., 2011). Thus, while treating liver metastases with
SBRTgenerallydoesnotrequirecontouringof theribs,werecom-
mend contouring those cases where the liver lesion resides within
2cm of the rib using suitable dose constraints (Pettersson et al.,
2009).
One would expect tumor size to be a signiﬁcant prognos-
ticator for local control based on basic radiobiologic princi-
ples; however the SBRT literature does not support this con-
cept. In the pooled experience reported by Chang et al. (2011),
tumor size did not predict local control in multivariate analysis.
Tumor size was not predictive of local control in the series by
Vautravers-Dewas et al. (2011) who analyzed local control for
tumor sizes less than or greater than 25mm. Our series, as well,
revealednosigniﬁcanttumorsizeeffectinunivariateanalysis,sug-
gesting that high-dose SBRT can overcome the decrease in local
controlusuallyseenwithincreasedtumorvolumeafterprotracted
fractionation conventional radiotherapy.
Assessment of local control following SBRT has historically
included CAT scan, MRI scan, and more recently PET/CT. Lim-
itations exist with anatomic tumor response metrics using CT
andMRIincludingWHOcriteria,RECISTandRECIST1.1which
depend on tumor size change. Also it is known that the sensi-
tivity and speciﬁcity for detection of liver metastases and local
liver recurrence improves with PET/CT compared to CT scanning
(Pateletal.,2011).ThecurrentseriesdependedheavilyonPET/CT
for local control assessment (Table 2). The beneﬁt of PET/CT
is not only that anatomic change is visualized and size is mea-
sured, but that the metabolic tumor activity can also be assessed
and compared to pretreatment. In the current experience, the
authors believe there is less ambiguity with increased conﬁdence
regarding coding of local control and failure with PET/CT. The
Table 3 | Review of stereotactic body radiation therapy for liver metastases and liver tumors.
Author Number of
Primary/Met
patients
Dose (Gy) BED Gy10
(EQD2)
Median
follow-up
(months)
Local
control
evaluation
2year
local
control
2year
overall
survival
Wulf et al. (2006) 5/39 26–37 .5Gy/
1–4 fx
48–93
(40–78)
15 CT/MRI 66%,
82%
BED>79
32%
Ambrosino et al. (2009) 27 mets med 36Gy/3
fx (25–60Gy)
79.2 (66) 13 CT 74%
‡
93% crude
Rusthoven et al. (2009) 47 mets 36–60Gy,
60Gy/3 fx
79.2–
180
(66–150)
16 CT/MRI 92% 30% median 20.5m
Lee et al. (2009) 68 mets Median
41.8Gy/6 fx
36–120
(30–100)
10.8 CT/MRI 71%
†
47% at 18m median
17 .6m
Chang et al. (2011) 65 colorectal
mets
Median 42Gy
22–60Gy/
1–6 fx
82–120
(68–100)
14.4 CT/MRI,
PET/CT
55%,
71%
BED>79
38%
Goodman et al. (2010) 7/19 18–30Gy/1 fx 50–120
(42–100)
17 .3 PET/CT,
CT, MRI
77%
†
50.4% median 28.6m
Stintzing et al. (2010) 4/32 24Gy/1 fx 81.6 (68) 21.3 MRI 86% 62% median 25.1m
van der Pool et al. (2010) 20 colorectal
mets
37 .5Gy/3 fx,
45Gy/3 fx
84.4,
112.5
26 CT/MRI 74% 83% median 34m
Rule et al. (2011) 27 mets 30Gy/3 fx,
50Gy/5 fx,
60Gy/5 fx
60, 100,
132
20 CT/MRI 56, 89,
100% for
30-, 50-,
and 60-Gy
50, 67 , 56% for 30-,
50- and 60-Gy, median
37m
Vautravers-Dewas et al. (2011) 42 mets 40Gy/4 fx,
45Gy/3 fx
80–113
(66–94)
14.3 CT, MRI 86% 48%
Lanciano et al. (this article) 7/23 36–60Gy/3
fx, 50Gy/5 fx
79.2–
180
(66–150)
22 PET/CT,
CT or
MRI
57%,
75%
BED10
>100 Gy
31%, 42%
BED10>100 Gy
median 20m
†1year local control;
‡1year crude local control; fx, fractions; OS, overall survival.
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proposed PET/CT response criterion (PERCIST) would require a
30%declineinSUVforresponsewithcompleteresponsereserved
for resolution of metabolic activity (Wahl et al.,2009).
AsshowninTable 3,localcontrolratesareexcellentwithSBRT,
however, follow-up is short and most series include a heteroge-
neous group of patients with variable tumor types and volume,
previous treatment, liver size, and liver disease status. The expe-
rience of Hoyer et al. (2006) demonstrates long term survival is
possible with SBRT for liver/lung metastases from colorectal can-
cer with 86% local control at 2years and 13% 5-year survival
for a group of patients who were unresectable at presentation.
However,questions remain regarding how to deﬁne the CTV after
chemotherapy, the margins needed around the CTV, and beneﬁt
of additional diagnostic studies for treatment planning. CT with
contrast is used for treatment planning, but the value of MRI
and PET/CT to improve target deﬁnition and optimal merging of
these images with CT requires further research. Treatment mar-
gins vary in the literature, usually ranging from 5 to 15mm for
non-CyberKnife series and 3–10mm for CyberKnife series,where
motiontrackingallowsforsmallermargins.Anydosecomparison
mustincludetheprescriptionpoint(forourseriesgenerally5mm
margins were used and dose prescribed to the 60–80% isodose to
cover 95% of the PTV) since margins vary from series-to-series
making conclusions regarding dose response difﬁcult. Homoge-
neousseriesof patientswithlivermetastasesinmulti-institutional
trials treated on standard protocols are needed to further reﬁne
dose volume relationships, effect on local control and ultimately
survival. An international phase II study of CyberKnife SBRT,
sponsored by Accuray International, for hepatic metastases from
colorectalcanceriscurrentlyopenandenrollingpatients(Clinical-
Trials.govaccessnumberNCT01318447).Thestudyisrestrictedto
patients with 1–3 colorectal metastases with a cumulative tumor
volume of <10cm and delivers 45Gy in 3 fractions to the PTV
with8mmmarginonGTV.Tumorcontrolassessmentwillinclude
CT/MRI and PET/CT.
CONCLUSION
CyberKnife SBRT is an effective modality with good local con-
trol and low morbidity for metastatic disease to the liver or for
primary liver tumors which are unresectable or medically inop-
erable. The current dose response analysis suggests that a dose
>100Gy10 is necessary for optimal local control,however further
study is necessary to evaluate the dose response for primary and
metastatic lesions based on histology. Early detection of metasta-
tic disease with smaller tumor volume would ensure high doses of
SBRT could be delivered safely and improve the chances for local
control and dose escalation. Future study is necessary to examine
the use of SBRT in combination with chemotherapy in a multi-
modality program since metastatic disease remains the primary
pattern of failure.
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